Mexico Generic Drug Market by Product Type, Distribution Channel, End User 2024-2032
                     Mexico Generic Drug 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Acco r d ing  t o  t he  l a t es t  r ep o r t  b y  I M ARC  G r o up ,  t i t l ed  "M ex i co  G ener i c  D rug  
M ar ke t :  I nd ust ry  T r ends ,  Sha re ,  S i ze ,  G row t h ,  O ppo r t un i t y  a nd  For ecas t  202 4 -
2032 , "  t he  M ex ico  ge ne r i c  d r ug  m a r ke t  s i ze  i s  p r o jec t ed  t o  ex h ib i t  a  g r ow t h  r a t e  
( CAG R)  o f  5 . 6 1% du r in g  20 24 - 20 32 .
The  i n i t i a t i ve s  m a de  by  g ove r nm e n t  au t ho r i t ie s  t o  r educ e  m ed i ca l  co s t s  ac r oss  t he  
Report cou n t r y  a r e  t he  f ac t o r s  r es pons ib le  f o r  t h e  g r o w t h  o f  t he  M ex ico  gen e r i c  d r ug  
m ar ke t .  Ad d i t i ona l l y ,  t he  de m an d  f o r  gen e r i c  d r ugs  i s  esca la t i ng  as  gove r nm en t  
Highlight and au t h o r i t i es  a r e  a c t i ve l y  p r om ot ing  t he  us e  o f  gen e r i c  m ed ic a t i o ns  as  a  co s t - e f f ec t i ve  op t i on  t o  expe ns i ve  b r an ded  d r ug s ,  wh ich  i s  f ue l i ng  t h e  m a r ke t .  
Th i s  i s  pa r t i cu la r l y  im po r t an t  i n  a  coun t r y  whe r e  h ea l t hc a r e  spend ing  i s  s i g n i f i ca n t ,  
Description and  t he  po pu la t i on  o f t en  f ace s  h igh  ou t - o f - pock e t  expen ses  f o r  m ed ic a l  t r ea t m e n t s .  
M or eove r ,  t he  exp i r a t i o n  o f  pa t e n t s  f o r  sev e r a l  b lock bus t e r  d r ugs  has  a l so  ope ned  
t he  m ar ke t  t o  gene r i c  sub s t i t u t es ,  i nc r e as in g  com pe t i t i on  and  m a k ing  m ed ica t i o ns  
m or e  a f f o r da b le  f o r  t h e  ge ne r a l  popu la t i on .  
Reque st  f o r  a  PDF  sam pl e  o f  t h i s  re por t :  
h t t p s : / / www. im ar c g r ou p . com / m e x ico - g ene r i c - d r ug - m ar ke t / r eq ues t s am p le
Report Description
Mexico Gener ic  Drug Market  Trends:
The r i s ing  occur rence o f  ch ron ic  d iseases  inc lud ing  d iabetes and  card iovascu lar  a i lments  among the  
popula t ion  o f  Mex ico has esca la ted  the  demand fo r  con t inua l  med ica l  t rea tment ,  bo ls ter ing  the  gener ic  d rug  
marke t .  In  add i t ion  to  th is ,  manufac tu re rs  are  incent iv ized  to  p roduce  gener ic  drugs that  meet  the g rowing  
need for  sus ta inab le ,  long- term t rea tments ,  wh ich  i s  ac t ing  as  another  g rowth- induc ing fac tor .  Fur thermore ,  
regu la to ry  improvements  and  cer t i f i ca t ions  by  government  au thor i t ies  for  gener ic  d rugs  have  boos ted  pub l ic  
t rus t  and  acceptance ,  a l ign ing w i th  g loba l  s tandards fo r  qua l i ty  and  e f f icacy,  thereby  esca la t ing the market .  
The  in tegra t ion o f  gener ic  d rugs  in to  pub l i c  hea l th  programs and  la rge-sca le  procurement  by  government  
au thor i t ies  a re  cruc ia l  fac to rs  s t imu la t ing  market  g rowth .  These e f fo r ts  are  complemented  by  the  expand ing  
capabi l i t i es  o f  domest ic  pharmaceut ica l  companies ,  wh ich  are  inc reas ing ly  focus ing on  R&D to  p roduce  h igh-
qua l i ty  gener ic  d rugs and  a re  ant ic ipated to  d r ive  the Mex ico gener ic  drug marke t  in  the coming years .
View Report  TOC,  F igures and Tables :  h t tps: / /www. imarcgroup.com/mexico-gener ic -drug-market
Therapy Area Insights:
• Central  Nervous System
• Cardiovascular
• Dermatology
• Genitour inary/Hormonal
• Respiratory
• Rheumatology
Report • Diabetes
Segmentation • Oncology
• Others
Drug Delivery Insights:
• Oral
• In jectables
• Dermal/Topical
• Inhalers
Distribution Channel Insights:
• Retai l  Pharmacies
• Hospital  Pharmacies
Regional Insights:
• Northern Mexico
Report • Central  Mexico
Segmentation • Southern Mexico
• Others
How has the Mexico generic drug market performed so 
far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Mexico 
generic drug market?
What is the breakup of the Mexico generic drug market 
on the basis of therapy area?
Key 
What is the breakup of the Mexico generic drug market 
Questions on the basis of drug delivery?
Answered in What is the breakup of the Mexico generic drug market on the basis of distribution channel?
the Report What are the various stages in the value chain of the 
Mexico generic drug market? 
What are the key driving factors and challenges in the 
Mexico generic drug?
What is the structure of the Mexico generic drug market 
and who are the key players?
What is the degree of competition in the Mexico generic 
drug market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4    M e x i c o  G e n e r i c  D r u g  M a r k e t  -  I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     M a r k e t  D y n a m i c s
    4 . 3     I n d u s t r y  T r e n d s
    4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5    M e x i c o  G e n e r i c  D r u g  M a r k e t  L a n d s c a p e
    5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
    5 . 2     M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6    M e x i c o  G e n e r i c  D r u g  M a r k e t  -  B r e a k u p  b y  T h e r a p y  A r e a
    6 . 1     C e n t r a l  N e r v o u s  S y s t e m
        6 . 1 . 1  O v e r v i e w
        6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 2     C a r d i o v a s c u l a r
        6 . 2 . 1  O v e r v i e w
        6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
       
    6 . 3     D e r m a to l o g y
        6 . 3 . 1  O v e r v i e w
        6 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 3 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 4     G e n i t o u r i n a r y / H o r m o n a l
        6 . 4 . 1  O v e r v i e w
        6 . 4 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 4 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 5     R e s p i r a t o r y
        6 . 5 . 1  O v e r v i e w
Table of         6 . 5 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )        6 . 5 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 6     R h e u m a t o l o g y
        6 . 6 . 1  O v e r v i e w
Contents         6 . 6 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 6 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 7     D i a b e t e s
        6 . 7 . 1  O v e r v i e w
        6 . 7 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 7 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 8     O n c o l o g y
        6 . 8 . 1  O v e r v i e w
        6 . 8 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 8 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 9     O th e r s
        6 . 9 . 1  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 9 . 2  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
F o r  m o r e  i n f o r m a t io n ,  v i s i t :  
ht tps : / /www. imarcgroup .com/mex ico -gene r ic -drug -marke t / to
c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: